BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Rossi C, Jeong D, Wong S, McKee G, Butt ZA, Buxton J, Wong J, Darvishian M, Bartlett S, Samji H, Yu A, Binka M, Alvarez M, Adu PA, Tyndall M, Krajden M, Janjua NZ; BC Hepatitis Testers Cohort Team. Sustained virological response from interferon-based hepatitis C regimens is associated with reduced risk of extrahepatic manifestations. J Hepatol 2019;71:1116-25. [PMID: 31433302 DOI: 10.1016/j.jhep.2019.07.021] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Wang M, Zhao Y, Hu W, Zhao D, Zhang Y, Wang T, Zheng Z, Li X, Zeng S, Liu Z, Lu L, Wan Z, Hu K. Treatment of COVID-19 Patients with Prolonged Post-Symptomatic Viral Shedding with Leflunomide -- a Single-Center, Randomized, Controlled Clinical Trial. Clin Infect Dis 2020:ciaa1417. [PMID: 32955081 DOI: 10.1093/cid/ciaa1417] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
2 Liu CH, Kao JH. Reply to: "Sofosbuvir and the risk of kidney dysfunction". J Hepatol 2021;74:257-8. [PMID: 33071008 DOI: 10.1016/j.jhep.2020.09.028] [Reference Citation Analysis]
3 Butt ZA, Wong S, Rossi C, Binka M, Wong J, Yu A, Darvishian M, Alvarez M, Chapinal N, Mckee G, Gilbert M, Tyndall MW, Krajden M, Janjua NZ. Concurrent Hepatitis C and B Virus and Human Immunodeficiency Virus Infections Are Associated With Higher Mortality Risk Illustrating the Impact of Syndemics on Health Outcomes. Open Forum Infect Dis 2020;7:ofaa347. [PMID: 32964065 DOI: 10.1093/ofid/ofaa347] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
4 McPherson S, Gosrani S, Hogg S, Patel P, Wetten A, Welton R, Hallsworth K, Campbell M. Increased cardiovascular risk and reduced quality of life are highly prevalent among individuals with hepatitis C. BMJ Open Gastroenterol 2020;7:e000470. [PMID: 32847899 DOI: 10.1136/bmjgast-2020-000470] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
5 Schulte B, Schmidt CS, Manthey J, Strada L, Christensen S, Cimander K, Görne H, Khaykin P, Scherbaum N, Walcher S, Mauss S, Schäfer I, Verthein U, Rehm J, Reimer J. Clinical and Patient-Reported Outcomes of Direct-Acting Antivirals for the Treatment of Chronic Hepatitis C Among Patients on Opioid Agonist Treatment: A Real-world Prospective Cohort Study. Open Forum Infect Dis 2020;7:ofaa317. [PMID: 32875003 DOI: 10.1093/ofid/ofaa317] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
6 Hallsworth K, Gosrani S, Hogg S, Patel P, Wetten A, Welton R, McPherson S, Campbell MD. Association of exercise participation levels with cardiometabolic health and quality of life in individuals with hepatitis C. BMJ Open Gastroenterol 2021;8:e000591. [PMID: 33762303 DOI: 10.1136/bmjgast-2020-000591] [Reference Citation Analysis]
7 Cheng JS, Lin YS, Hu JH, Chang MY, Ku HP, Chien RN, Chang ML. Impact of Interferon-Based Therapy on Hepatitis C-Associated Rheumatic Diseases: A Nationwide Population-Based Cohort Study. J Clin Med 2021;10:817. [PMID: 33671397 DOI: 10.3390/jcm10040817] [Reference Citation Analysis]
8 Chuaypen N, Jinato T, Avihingsanon A, Chirapongsathorn S, Cheevadhanarak S, Nookaew I, Tanaka Y, Tangkijvanich P. Improvement of Gut Diversity and Composition after Direct-Acting Antivirals in HCV-Infected Patients with or without HIV Coinfection. J Infect Dis 2021:jiab094. [PMID: 33598686 DOI: 10.1093/infdis/jiab094] [Reference Citation Analysis]
9 Liu CH, Chen CY, Su WW, Tseng KC, Lo CC, Liu CJ, Chen JJ, Peng CY, Shih YL, Yang SS, Huang CS, Huang KJ, Chang CY, Tsai MC, Kao WY, Fang YJ, Chen PY, Su PY, Tseng CW, Huang JJ, Lee PL, Lai HC, Hsieh TY, Chang CH, Huang YJ, Lee FJ, Chang CC, Kao JH. Sofosbuvir/velpatasvir with or without low-dose ribavirin for patients with chronic hepatitis C virus infection and severe renal impairment. Gut 2022;71:176-84. [PMID: 33408122 DOI: 10.1136/gutjnl-2020-323569] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 13.0] [Reference Citation Analysis]
10 Adu PA, Rossi C, Binka M, Wong S, Wilton J, Wong J, Butt ZA, Bartlett S, Jeong D, Pearce M, Darvishian M, Yu A, Alvarez M, Velásquez García HA, Krajden M, Janjua NZ. HCV reinfection rates after cure or spontaneous clearance among HIV-infected and uninfected men who have sex with men. Liver Int 2021;41:482-93. [PMID: 33305525 DOI: 10.1111/liv.14762] [Reference Citation Analysis]
11 Moran CA, Collins LF, Beydoun N, Mehta PK, Fatade Y, Isiadinso I, Lewis TT, Weber B, Goldstein J, Ofotokun I, Quyyumi A, Choi MY, Titanji K, Lahiri CD. Cardiovascular Implications of Immune Disorders in Women. Circ Res 2022;130:593-610. [PMID: 35175848 DOI: 10.1161/CIRCRESAHA.121.319877] [Reference Citation Analysis]
12 Jeong D, Karim ME, Wong S, Wilton J, Butt ZA, Binka M, Adu PA, Bartlett S, Pearce M, Clementi E, Yu A, Alvarez M, Samji H, Velásquez García HA, Abdia Y, Krajden M, Janjua NZ. Impact of HCV infection and ethnicity on incident type 2 diabetes: findings from a large population-based cohort in British Columbia. BMJ Open Diabetes Res Care 2021;9:e002145. [PMID: 34099439 DOI: 10.1136/bmjdrc-2021-002145] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
13 Binka M, Janjua NZ, Grebely J, Estes C, Schanzer D, Kwon JA, Shoukry NH, Kwong JC, Razavi H, Feld JJ, Krajden M. Assessment of Treatment Strategies to Achieve Hepatitis C Elimination in Canada Using a Validated Model. JAMA Netw Open 2020;3:e204192. [PMID: 32374397 DOI: 10.1001/jamanetworkopen.2020.4192] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
14 Rockey DC, Friedman SL. Fibrosis Regression After Eradication of Hepatitis C Virus: From Bench to Bedside. Gastroenterology 2021;160:1502-1520.e1. [PMID: 33529675 DOI: 10.1053/j.gastro.2020.09.065] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
15 Li J, Gordon SC, Zhou Y, Boscarino JA, Schmidt MA, Daida YG, Rupp LB, Trudeau S, Lu M; CHeCS Investigators. Sex Differences in Extrahepatic Outcomes After Antiviral Treatment for Hepatitis C. Am J Gastroenterol 2021;116:576-83. [PMID: 33399360 DOI: 10.14309/ajg.0000000000001095] [Reference Citation Analysis]
16 Ma SH, Tai YH, Dai YX, Chang YT, Chen TJ, Chen MH. Association between hepatitis C virus infection and subsequent chronic inflammatory skin disease. J Dermatol 2021. [PMID: 34460962 DOI: 10.1111/1346-8138.16129] [Reference Citation Analysis]
17 Elsharkawy A, Samir R, El-Kassas M. Fibrosis regression following hepatitis C antiviral therapy. World J Hepatol 2022; 14(6): 1120-1130 [DOI: 10.4254/wjh.v14.i6.1120] [Reference Citation Analysis]